| pubmed-article:8608441 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C0728724 | lld:lifeskim |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C0080103 | lld:lifeskim |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C0006230 | lld:lifeskim |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C0282171 | lld:lifeskim |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C1522609 | lld:lifeskim |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C1554112 | lld:lifeskim |
| pubmed-article:8608441 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
| pubmed-article:8608441 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8608441 | pubmed:dateCreated | 1996-5-29 | lld:pubmed |
| pubmed-article:8608441 | pubmed:abstractText | Effects of the dopamine-related drug bromocriptine (BCT) on event-related potentials (ERP) were investigated in 18 healthy volunteers. Bromocriptine 2.5 mg or an inactive placebo was administered according to a completely randomized double-blind, cross-over design. The ERP were recorded 3 h after medication was given. Although BCT prolonged the P300 latency, it had no effect on the amplitudes of the ERP components as a whole. Bromocriptine increased the latencies of N100, P200 and P300 in the respective short-latency subject group, and decreased the latency of N200 in the long-latency subject group. It increased the amplitude of N200 in the low-amplitude subject group. It was concluded that the prolongation of P300 latency as a whole and the different responses that take place are dependent on the initial values and were recognized in the effect of a single administration of BCT 2.5 mg. The results of this study are discussed in relation to the law of initial value. | lld:pubmed |
| pubmed-article:8608441 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8608441 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8608441 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8608441 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8608441 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8608441 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8608441 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8608441 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8608441 | pubmed:issn | 1323-1316 | lld:pubmed |
| pubmed-article:8608441 | pubmed:author | pubmed-author:OguraCC | lld:pubmed |
| pubmed-article:8608441 | pubmed:author | pubmed-author:NishimuraNN | lld:pubmed |
| pubmed-article:8608441 | pubmed:author | pubmed-author:OhtaII | lld:pubmed |
| pubmed-article:8608441 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8608441 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:8608441 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8608441 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8608441 | pubmed:pagination | 79-86 | lld:pubmed |
| pubmed-article:8608441 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:meshHeading | pubmed-meshheading:8608441-... | lld:pubmed |
| pubmed-article:8608441 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8608441 | pubmed:articleTitle | Effects of the dopamine-related drug bromocriptine on event-related potentials and its relation to the law of initial value. | lld:pubmed |
| pubmed-article:8608441 | pubmed:affiliation | Department of Neuropsychiatry, School of Medicine, University of the Ryukyus, Okinawa, Japan. | lld:pubmed |
| pubmed-article:8608441 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8608441 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8608441 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8608441 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8608441 | lld:pubmed |
